Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

P. Sonneveld; E. Asselbergs; S. Zweegman; B. van der Holt; M.J. Kersten; E. Vellenga; M. van Marwijk-Kooy; A. Broyl; O. de Weerdt; S. Lonergan; A. Palumbo; H.M. Lokhorst

doi:10.1182/blood-2014-05-576256

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

P. Sonneveld, E. Asselbergs, S. Zweegman, B. van der Holt, M.J. Kersten, E. Vellenga, M. van Marwijk-Kooy, A. Broyl, O. de Weerdt, S. Lonergan, A. Palumbo, H.M. Lokhorst

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	449-456
Journal	Blood
Volume	125
Issue number	3
DOIs	https://doi.org/10.1182/blood-2014-05-576256
Publication status	Published - 2015

Access to Document

10.1182/blood-2014-05-576256

Cite this

Sonneveld, P., Asselbergs, E., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Broyl, A., de Weerdt, O., Lonergan, S., Palumbo, A., & Lokhorst, H. M. (2015). Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood, 125(3), 449-456. https://doi.org/10.1182/blood-2014-05-576256

@article{1401afd05ee84c399f31e506aef59a5e,

title = "Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma",

author = "P. Sonneveld and E. Asselbergs and S. Zweegman and {van der Holt}, B. and M.J. Kersten and E. Vellenga and {van Marwijk-Kooy}, M. and A. Broyl and {de Weerdt}, O. and S. Lonergan and A. Palumbo and H.M. Lokhorst",

year = "2015",

doi = "10.1182/blood-2014-05-576256",

language = "Undefined/Unknown",

volume = "125",

pages = "449--456",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "3",

}

Sonneveld, P, Asselbergs, E, Zweegman, S, van der Holt, B, Kersten, MJ, Vellenga, E, van Marwijk-Kooy, M, Broyl, A, de Weerdt, O, Lonergan, S, Palumbo, A & Lokhorst, HM 2015, 'Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma', Blood, vol. 125, no. 3, pp. 449-456. https://doi.org/10.1182/blood-2014-05-576256

TY - JOUR

T1 - Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

AU - Sonneveld, P.

AU - Asselbergs, E.

AU - Zweegman, S.

AU - van der Holt, B.

AU - Kersten, M.J.

AU - Vellenga, E.

AU - van Marwijk-Kooy, M.

AU - Broyl, A.

AU - de Weerdt, O.

AU - Lonergan, S.

AU - Palumbo, A.

AU - Lokhorst, H.M.

PY - 2015

Y1 - 2015

U2 - 10.1182/blood-2014-05-576256

DO - 10.1182/blood-2014-05-576256

M3 - Article

C2 - 25398935

SN - 0006-4971

VL - 125

SP - 449

EP - 456

JO - Blood

JF - Blood

IS - 3

ER -